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Abstract
Angiotensin converting enzyme (ACE)-inhibitors are effective in patients with 
mild to moderately severe hypertension, collagen vascular and cardiovascular 
disease. They are also used in the prevention and treatment of myocardial infarc-
tion and in the management of cardiac arrhythmias. Patients with cardiovascular 
diseases are generally on multiple medicines that’s why it is imperative to study 
drug–drug interactions of medicines which are commonly taken together in any 
given case, as combined administration of different medicines can significantly 
influence the availability of drugs. In the present study we investigated the “in vitro” 
interactions of ACE inhibitors (enalapril, captopril and lisinopril) with frequently 
prescribed and co-administered drugs in simulated human body environments. 
These interactions were monitored by means of UV spectrophotometry and separa-
tion technique as RP-HPLC. Prior to start of actual drug interactions, the method 
of analysis of each drug was established and its various parameters validated for 
considering its use in testing of drug in vitro as well as in human serum. For this 
purpose, an attempt was made to develop a number of new HPLC methods for 
determination of ACE inhibitors (enalapril, captopril and lisinopril) and simultane-
ously with interacting drugs. These methods were optimized, validated and then 
successfully employed for the quantitation of enalapril, captopril and lisinopril and 
selected drugs in interactions studies. As a result, new methods for the quantita-
tion of individual as well as multiple drugs were developed. The interacting drugs 
selected were antidiabetic drugs (metformin, glibenclamide, glimepride and piogli-
tazone. Interaction consequences revealed that the availability of enalapril was not 
affected in presence of antidiabetic drugss whereas the availability of captopril and 
lisinopril were altered in presence of NIDDMs.
Keywords: ACE Inhibitors, Antidiabetics, Interaction studies, HPLC,  
Method development
1. Introduction
1.1 Angiotensin converting enzyme
Angiotensin Converting Enzyme is an ectoenzyme and a glycoprotein with an 
appreciate molecular weight of 170,000 Do. Human angiotensin converting enzyme 
contains 277 aminoacid residues and has two homologous domains, each with a 
catalytic site and a region for binding Zn+2 [1, 2]. The degradation of bradykinin 
to inactive peptides occurs via action of ACE, thus ACE not only produces a potent 
vasoconstricton but also inactivates a potent vasodilator [3].
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In 1965, Ferreira [4] studied the physiological effects of snake poisoning and 
discovered a specific component from the venom of the pit viper, bothrops jararaca, 
which inhibits degradation of the peptide bradykinin and potentiate hypotensive 
action of bradykinin. These factors originally designated as bradykinin potentiating 
factors (BPFs), were isolated and found to be a family of peptides containing 5–13 
amino acid residues. Bakhle [5] reported that these same peptides had an inhibitory 
activity on ACE of dog lung homogenate and inhibited the enzymatic conversion of 
angiotensin I to angiotensin II. Hans Brunner and John Laragh [6] administered it to 
hypertensive patients and showed that it was extremely effective in lowering blood 
pressure. The structural requirements for substrates of angiotensin converting 
enzyme to cleave a substrate are found similar to those observed with carboxypep-
tidase A of bovine pancrease [7, 8]. The substrate specificity and other properties of 
angiotensin converting enzyme suggested that it was a zinc metallopeptidase, simi-
lar in mechanism to carboxypeptidase A, an enzyme whose active site had been well 
characterized by x-ray crystallography and other methods [9]. In 1970, Ferreira and 
Greene [10] isolated and characterized the first peptide, a bradykinin-potentiating 
pentapeptide that they called BPP5a; it also inhibited ACE and transiently lowered 
blood pressure in animal models. The significance of ACE in the pathogenesis of 
hypertension was not fully appreciated until 1977’s, when Ondetti [11] first isolated 
and then synthesized the naturally occurring nonpeptide, teprotide. He proposed a 
hypothetical model of the active site of ACE and used it to predict and design com-
pounds that would occupy the carboxy- terminal binding site of the enzyme [12]. 
Cushman and Ondetti first created succinyl-L-proline, which showed slight positive 
activity. Inhibitory activity increased 15 to 20 times when they substituted a methyl 
group in the 2 position of succinyl group. Finally to enhance the binding capacity of 
substrate structure and zinc of the enzyme they replaced succinyl COOH with sulf-
hydryl, a 2000 times increase in inhibitory potency was achieved. ACE inhibitors 
entered the antihypertensive drug market during the 1980. Manolio [13] explored 
new types of drugs in preventing cardiovascular mortality. Captopril, a specific 
potent inhibitor of ACE, showed excellent anti-hypertensive properties in clinical 
trials and had a major impact on the treatment of cardiovascular disease [14].
1.1.1 Chemistry
The most thoroughly studied of the peptide inhibitors of converting enzyme is 
the nonapeptide known as teprotide, having the structure, Pyoglu-Tro-Arg-Pro-
Glnlle-Pro-Pro.Teprotide acts as a competitive inhibitor of converting enzyme, with 
an affinity for the enzyme much higher than that of angiotensin I. It is not itself a 
substrate for the enzyme. Although converting enzyme will cleave many differ-
ent C-terminal dipeptide residues, it will not cleave peptides with proline in the 
penultimate position. As noted, the penultimate proline in angiotensin II, indeed, 
is responsible for its refractoriness to further cleavage by converting enzyme. 
Moreover, the presence of Pyro Glu at the N-terminus renders teprotide refrac-
tory to amino peptidases; this confers further stability and effectiveness in vivo. 
Nevertheless, teprotide has a relatively short duration of action and must be given 
parentally to be effective [11]. The optimum pH of angiotensin converting enzyme 
was found to vary with the substrate employed and to be influenced by the presence 
or absence of chloride ion. With longer peptide substrates such as angiotensin I or 
bradykinin in the presence of chloride ion, the optimal pH for hydrolytic action 
of the converting enzyme was about 7.5; with tripeptide substrates such as Z-Phe-
His-Leu, Hip-His-Leu, or Hip-Gly-Gly, it was about pH 8.5 [15, 16]. Studies of the 
hydrolysis of synthetic substrate of ACE [17, 18] and hippuryl di and tripeptides 
[19] shows that enzyme tolerate changes at antepenultimate position of a peptide 
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substrate especially aromatic amino acids such as phenylalanine which contributes 
greatly to the overall affinity for the enzyme. A tripeptide with an acylated terminal 
amino group is the simplest peptide cleaved by the enzyme. However, the tripeptide 
Z-Phe-His-Leu, analogous to the terminal tripeptide sequence of angiotensin I, 
binds to the active site of angiotensin converting enzyme as well as the intact deca-
peptide. Peptides such as angiotensin II with a penultimate proline residue [20]. The 
orally effective ACE-inhibitor was developed by a rational approach that involved 
analysis of the inhibitory action of teprotide, inferences about the action of con-
verting enzyme on its substrates, and analogy with carboxy peptidase A, which was 
known to be inhibited by d-benzylsuccinic acid. Ondetti and Cushman urged that 
inhibition of converting enzyme might be produced by succinyl amino acids that 
corresponded in length to the dipeptide cleaved by converting enzyme. This proved 
to be true and led ultimately to the synthesis of a series of carboxy or mercapto 
alkanoyl derivatives that acted as competitive inhibitors of the enzyme [21].
1.1.2 Mechanism of action
These drugs block the angiotensin converting enzyme that cleaves the terminal 
two peptides from angiotensin I (decapeptide) to form the potent vasoconstrictor 
angiotensin II (octapeptide) [22, 23] and lower the BP by reducing peripheral vas-
cular resistance without reflexly increasing cardiac out put rate, and contractility 
[22]. They also inhibit the rate of bradykinin inactivation thus resulting in vasodila-
tion, they also decrease the secretion of aldisterone resulting in decrease of sodium 
and water retention.
1.1.3 Pharmacokinetics
ACE-inhibitors are given by mouth, the oral bioavailability of this class of 
drugs ranges from 13–95% [24, 25]. Most of the ACE inhibitors are administered 
as prodrugs that remain inactive until esterified in the liver [26]. Fosinoprilate is 
excreted via biliary duct, elimination of the diacid is polyphasic and there is a pro-
long terminal elimination phase, which is considered to represent binding to ACE 
at saturate binding site. This bond fraction does not contribute to accumulation of 
drug following multiple doses [27, 28].
1.1.4 Therapeutic use
ACE-inhibitors are effective in patients with mild to moderately severe hyper-
tension, with normal or low plasma renin activity, with collagen vascular disease, 
with cardiovascular and in anephric disease [29–36]. They cause a reduction in 
left ventricular hypertrophy, and in plasma fibrinogen level [37, 38]. They are also 
used in the prevention and treatment of myocardial infarction [39, 40], and in the 
management of cardiac arrhythmias [41, 42]. They can decrease the progression of 
atherosclerosis [43], microalbuminuria [44] and diabetic retinopathy [45–47] and 
produce beneficial effect in Bartter’s syndrome [48].
1.1.5 Adverse effects
Pronounced hypertension may occur at the start of therapy with ACE-inhibitors 
particularly in patients with heart failure, and in sodium or volume depletion 
patients [49–51]. They cause hyperkalemia in patients with renal insufficiency or in 
patients taking k + −sparing diuretic, k + −supplement, beta blockers or NSAID’s 
[23, 52] and produce cough in hypertensive patient [53, 54]. Altered liver function, 
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cholestatic jaundice, hepatitis, hepatotoxicity [55] and aplastic anemia [56] have 
also been reported. They can produce a complex and contradictory effect on kidney 
and induce renal insufficiency in patients having bilateral renal artery stenosis, 
heart failure or diarrhea [57–61]. Angioedema is a rare but potentially life-threaten-
ing side effect of ACE inhibitors [62–68] can cause a number of fetal anomalies  
[69, 70]. Scalded mouth syndrome [71] and drug induced pulmonary-infiltration 
with eosinophilia syndrome (PIE-syndrome) is a rare complication [72]. With use 
of ACE inhibitors, anaphylactoid reactions are also reported [73, 74].
1.1.6 Contraindications
Experimental and clinical data conclude that use of ACE inhibitors should be 
avoided in all trimester of pregnancy [75, 76]. Patients with peripheral vascular 
disease are at high risk of renal failure with this therapy [77] also contraindicated in 
known hypersensitivity to any ACE inhibitors [78].
1.1.7 Overdosage
There have been reports of over dosages with captopril and enalepril [79–81], 
the main effect is hypotension [82, 83] which usually responds to supportive 
treatment and volume expansion, pressor agents are rarely required. Infusion of 
angiotensin amide may be considered if hypotension persists [84, 85].
1.1.8 Drug interactions
Hypotensive effect of ACE inhibitors decreased when given in combination 
with non-steroidal anti-inflammatory drugs [86] but this effect is enhanced with 
calcium-channel blockers [87] and beta-blockers [88]. Granulocytopenia occurs 
after combine therapy of ACE inhibitors and interferones [89], the nitritoid reac-
tion occurs with concomitant use of gold salt and ACE inhibitors [90]. Cytokines 
antagonize the hypotensive effect of ACE inhibitors [91], severe hypokalaemia occurs 
with potassium depleting diuretics [92] and potassium-sparing diuretics produced 
hyperkalaemia [93–95]. ACE inhibitors could increase potassium levels in the body 
[96, 97]. Alpha-blockers enhance hypotensive effect of ACE inhibitors [98]. Iron 
supplementation successfully decreases cough induced by ACE-inhibitors [99] and 
can interfere with the absorption of ACE inhibitors [100]. Hypoglycemic effect is 
enhanced with antidiabetics and insulin [101, 102]. Azathioprine and ACE inhibitors 
combination is associated with anemia [103]. Marked hypotension occurs in patients 
receiving general anesthetics and ACE inhibitors [104]. The risk of bone marrow 
depression is increased in patients taking concomitant therapy of ACE-inhibitors and 
immunosuppressive agents [76]. Table 1 shows some example of ACE Inhibitors.
1.2 Antidiabetic drugs
Type II or non insulin dependent diabetes mellitus (NIDDM) formerly known 
as maturity-onset or adult-onset diabetes. Approximately 95% of patients are being 
affected by the type II form [105, 106]. NIDDM are being increasingly diagnosed 
as its importance as a risk factor for the development of cardiovascular disease and 
many drugs has been known to interfere with glucose control. The greatest effect 
was seen with propranolol and the least with cardioselective and less lipophilic 
beta-blockers, nifedipine has been associated with deterioration in glucose con-
trol but verapamil has been found to have a beneficial effect on glucose control. 
Antihypertensive drug clonidine has not been shown to result in deterioration in 
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glucose control when used in NIDDM. Long term therapy with the more specific 
agonist guanfacine was reported to have a beneficial effect on glucose tolerance 
[107]. Table 2 shows, examples of antidiabetic drugs.
2. Experimental
2.1 Materials
Raw materials used were of pharmaceutical purity and were obtained from 
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pharmacy and each product was labeled and expiry date not earlier than two years, 
at the time of these studies were noted.
2.1.1 Reagents
Analytical grade reagents were used during the whole experimental procedures. 
Methanol and acetonitrile were of (HPLC grade) (TEDIA®, USA). Other reagents 
include hydrochloric acid, sodium hydroxide, sodium chloride, potassium dihydro-
gen orthophosphate, disodium hydrogen orthophosphate, ammonium chloride, 
10% NH3 solution, phosphoric acid 85% (Merk, Germany). Organic solvents used 
were methanol, ethanol, ethyl acetate, chloroform, acetronitrile, triethylamine and 
DMSO (Merck Grade).
2.1.2 Equipments
UV visible spectrophotometer (Model 1601, Shimadzu, Japan) with 10-mm 
path length connected to a P-IV computer loaded with Shimadzu UVPC version 3.9 
software was used in these studies. Deionizer, Stedec CSW-300 used for deionization 
of water. The dissolution equipment was the B.P. 2009 standards. Chromatographic 
studies were carried out by using two Shimadzu HPLC systems, one equipped with 
LC-10 AT VP pump, SPD-10 A VP UV–vis detector and other HPLC system was 
equipped with LC-20AT and SPD-20A UV/VIS detector utilizing Hypersil, ODS, C18 
(150 × 4.6 mm, 5micron) and Purospher® STAR RP-18 column. Chromatographic 
data were recorded using a CBM-102 Shimadzu. Shimadzu Class-GC 10 software 
(version 2) for data acquisition and mathematical calculations.
IR studies were carried out by FTIR Prestige-21 spectrophotometer Shimadzu. 
Spectral treatment was performed using Shimadzu IRsolution 1.2 software. The 
H1-NMR spectra were recorded on a Bruker AMX 500 MHz spectrometer using 
TMS as an internal standard. Melting points were recorded by Gallenkamp melting 
point apparatus.
2.2 Methods
2.2.1 Preparation of simulated gastric juice and buffers
0.1 N hydrochloric acid was prepared by diluting 9 mL hydrochloric acid of 
analytical grade (11 N) in a liter volumetric flask and the volume was made up to 
the mark with de-ionized water. Chloride buffer of pH 4 was prepared by dissolving 
Class Drugs Brands Potency 
(mg)
Pharmaceutical industry
ACE inhibitors Enalapril Renitec 10 MSD
Captopril Capoten 25 Bristol Meyers Pvt. Ltd
Lisinopril Lisinopril 5 Atco Laboratories Ltd
Antidiabetic Metformin Neodipar 250 Sanofi Aventis (Pakistan) Ltd
Glimepride Amaryl 2 Sanofi Aventis (Pakistan) Ltd
Pioglitazone Poze 45 Ali Goliar Pharmaceuticals (Pvt
Glibenclamide Diazet 5 Safe Pharmaceutical (Pvt) Ltd
Table 3. 
Drugs, brands and manufacturers.
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3.725 g of potassium chloride in deionized water in one liter and 0.1 N HCl was used 
for pH adjustment. For preparation of phosphate buffer of pH 7.4, 0.6 gm of potas-
sium dihydrogen orthophosphate, 6.4 g of disodium hydrogen orthophosphate and 
5.85 g of sodium chloride were dissolved in sufficient deionized water to produce 
1000 mL and the pH adjusted. For preparation of ammonia buffer of pH 9, 4.98 g of 
ammonium chloride was dissolved in 1000 mL of deionized water and pH adjusted 
with 10% ammonia.
2.2.2 Construction of the calibration curve of drugs
The above prepared working standard solutions of all drugs were scanned in 
the region 200–700 nm against the reagent blank and absorbance maxima was 
recorded as shown in Table 4. Calibration curves were constructed between con-
centration and absorbance. Epsilon values and linear coefficients were calculated 
in each case at all above described pH values. Beer Lambert’s law was obeyed at all 
concentrations and pH.
2.2.3  Monitoring of drug interactions of enalapril, captopril and lisinopril by high 
performance liquid chromatography
HPLC methods for simultaneous determination of enalapril, captopril and 
lisinopril with NSAIDs, H2-receptor antagonist, statins, antidiabetic drugs, metals 
and antacids in raw materials, pharmaceutical dosage forms or in human serum are 
developed and validated according to ICH guidelines. These methods were then 
applied to drug–drug, drug metals and drug antacid interaction studies.
2.2.4 Chromatographic conditions
The isocratic elution was performed at ambient temperature with two different 
types of columns. Hypersil, ODS, C18 (150 × 4.6 mm, 5micron) and Purospher® 
STAR RP-18, for assay of enalapril, captopril and lisinopril and simultaneous 
determination of these drugs with interacting drugs respectively. The mobile phase, 
flow rate, wavelength UV detection were varied as cited in Table 5. Sample volume 
of 20 μL was injected in triplicate onto the HPLC column and elute was monitored 
at different wavelengths.
2.2.5 Preparation of standard solutions
Stock reference standard solutions of all drugs were prepared daily by dissolv-
ing appropriate amounts of each drug in mobile phase to yield final concentrations 
Class of drugs Analytes Wavelength (nm) Cone.range (m Mole)
ACE inhibitors Enalapril 203, 206, 207, 208 1–9 x 10−5
Captopril 203, 204, 206 5–14 x 10−7
Lisinopril 206 1–10 x 10−5
Antidiabetic drugs Metformin 205, 223 0.01–0.1
Glimepride 240 0.01–0.1
Glibenclamide 231, 238, 246 0.01–0.1
Pioglitazone 225, 269 0.01–0.1
Table 4. 
Absorbance maxima.
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300 μg mL−1. For the calibration standards, calibrators of each drug were prepared 
by making serial dilutions from stock solutions. All solutions were filtered through 
0.45 μm filter and degassed using sonicator.
2.2.6 Preparation of pharmaceutical dosage form samples
Pharmaceutical formulations of the respective brands, commercially available 
in Pakistan were evaluated. In each case, groups of twenty tablets were individually 
weighed and finely powdered in a mortar. Weighed portion of the powder equiva-
lent to the suitable amount of drug (according to the labeled claimed) was trans-
ferred into a 100 mL volumetric flask completely dissolved in mobile phase and 
then diluted with this solvent up to the mark, a portion of this solution was filtered 
through a disposable 0.45 μm filter and then injected.
2.2.7 Preparation of standard drug plasma solutions
Blood samples were collected from healthy volunteers and then centrifuged 
at 3000 rpm for 10 minutes and supernatant was stored at −20°C. After thawing, 
serum was deprotinated by acetonitrile and spiked daily with working solutions to 
produce desired concentrations of enalapril and interacting drugs. 10 μL volume of 
each sample was injected and chromatographed under above conditions.
2.3 Method development and optimization
HPLC methods were developed and optimized for certain parameters before 
method validation. The optimization of the analytical procedure has been carried 
out by varying the mobile phase composition, flow rate, pH of the mobile phase, 
diluents of solutions and wavelength of analytes in order to achieve symmetrical 
peaks with good resolution at reasonable retention time.
2.3.1 Method validation
All validation steps were carried out according to the ICH guidelines such as system 
suitability, selectivity, specificity, linearity (concentration–detector response relation-
ship), accuracy, precision and sensitivity i.e. detection and quantification limit.
2.3.2 System suitability
System suitability of the method was evaluated by analyzing five replicate 
analyses of the drug at a specific concentration for repeatability, peaks symmetry 
Drugs Mobile phase pH Flow rate Detection
MeOH ACN H2O mLmin
−1 Nm
Enalapril assay 70 — 30 3.5 1 215
Enalapril+Antidiabetic drugs 70 30 2.8 1 230
Captopril 50 — 50 2.9 1 220
Captopril +Antidiabetic drugs 70 30 3 1 230
Lisinopril 80 2.5 17.5 3 1 225
Lisinopril+Antidiabetic drugs 80 20 3 1 225
Table 5. 
Chromatographie conditions of HPLC methods.
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(symmetry factor), theoretical plates of the column, resolution between the peaks 
of enalapril and other drugs, mass distribution ratio (capacity factor) and relative 
retention.
2.3.3 Specificity and linearity
The drugs were spiked with pharmaceutical formulations containing different 
excepients. The linearity of the method was evaluated at different concentrations 
with different groups. Linear correlation coefficient, intercept and slope values 
were calculated for statistical analysis.
2.3.4 Accuracy and precision
The accuracy of the method was calculated at three concentration levels (80, 100 
and 120%) by spiking known quantities of the drug analytes. Three injections of each 
solution were injected to HPLC system and % recovery was calculated in each case.
For the precision of the method, six replicates of each level were injected to sys-
tem on two different non-consecutive days in each case and %RSD was calculated.
2.3.5 Limit of detection and quantification
Detection limit (LOD) of the method was calculated by the formula LOD = 3.3 
SD/slope. The quantitation limit (LOQ ) is the lowest level of analyte that is accu-
rately measured and it was evaluated as ten times the noise level LOQ =10ơ/S; 
where ơ is the standard deviation of the lowest standard concentration and S is the 
slope of the standard curve.
2.3.6 Robustness
Robustness was performed by making minor changes in the percentage of 
mobile phase (methanol, water and acetonitrile) wave length, pH and flow rate. 
Therefore, five repeated samples were injected under small variations of each 
parameter. When a parameter was changed ±0.2% (in flow rate), ± 0.2% pH 
and ± 5% wave length from its optimum condition.
2.3.7 Ruggedness
Ruggedness of our method was determined in two different labs. Lab 1 was the 
Research Institute of Pharmaceutical Sciences, Department of Pharmaceutical 
Chemistry, Faculty of Pharmacy, University of Karachi while other lab was lab 9, 
Department of Chemistry, Faculty of Science, University of Karachi. Two different 
instruments one was LC 10 and LC 20. Two different columns Purospher STAR C18 
and Hypersil ODS were used.
2.3.8 Interaction studies by HPLC
Enalapril solution was mixed with each solution of interacting drug separately 
that gave the final concentration of 100μgmL−1 for each constituent. These were 
kept in water bath maintained at 37°C for 3 hours. An aliquot of 5 mL was with-
drawn after every 30 minutes intervals, after making appropriate dilutions was fil-
tered through 0.45 μ filter paper and three replicates were injected to HPLC system. 
The concentration of each drug was determined and % recovery was calculated and 
the same procedure was applied for captopril and lisinopril.
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3. Result and discussion
3.1  Simultaneous quantitation of enalapril and antidiabetic drugs  
(metformin, glibenclamide and glimepiride)
There are number of HPLC methods reported for the quantitation of met-
formin using UV detector [108, 109] liquid chromatography–tandem mass 
spectrometry [110] and from human plasma [111]. Moreover, there are many 
methods reported for the simultaneous analysis of metformin with other anti-
diabetics [112, 113]. Likewise, there are methods reported for the analysis of 
glibenclamide from pharmaceutical formulations [114], human plasma [115, 116] 
using HPLC. Similarly, there are methods reported for the simultaneous analysis 
of glibenclamide with other anti-diabetics. However, no method reported in the 
literature for the simultaneous quantitation of enalapril, metformin, gliben-
clamide and glimepride.
3.1.1 Method optimization and chromatographic conditions
In the present investigation the best separation of enalapril and antidiabetic 
drugs was achieved using a Hypersil, ODS, C18 (150 × 4.6 mm, 5micron) column 
which provides efficient and reproducible separation of the components. Using 
other type of column under similar experimental condition, the separation lasted 
about 11 minutes. A mobile phase of methanol: water (70:30 v/v) having pH 
adjusted with phosphoric acid to 2.8 provided a reproducible, baseline resolved 
peak. Small changes in pH of the mobile phase had a great influence to the chro-
matographic behavior of these drugs, higher pH of the mobile phase also results in 
peak tailing and at a lower pH retention time of antidiabetic drugs and enalapril 
was delayed. It is obvious from the chromatogram (Figure 1) that antidiabetic drugs 
and enalapril eluted out forming symmetrical peaks and were well separated from 
each other. The method was found to be rapid as the drugs separated in a very short 
time i.e. enalapril 3.6 min and metformin, glibenclamide and glimepiride elution 
time was 2.4, 8.5 and 10.9 min respectively, which is important for routine analysis. 
The advantages of this method are ease of operation, short analysis time (total run 
time < 12 minutes), utilization of readily available cost-effective solvents, no matrix 
interferences, and satisfactory limit of quantification to enable pharmacokinetic 
studies of enalapril and NIDDMs.
3.1.2 Method validation
The developed method was validated by ICH guidelines [117]. It includes 
various parameters for example system suitability, selectivity, specificity, linearity, 
accuracy test, precision, robustness, ruggedness, sensitivity, limit of detection and 
quantification.
3.1.2.1 System suitability
The HPLC system was equilibrated with the initial mobile phase composition, 
followed by 6 injections of the same standard to evaluate the system suitability on 
each day of method validation. Parameters of system suitability are peaks symme-
try (symmetry factor), theoretical plates of the column, resolution, mass distri-
bution ratio (capacity factor) and relative retention as summarized in Table 6.
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3.1.2.2 Linearity
Linearity is generally reported as the variance of the slope of the regression line. 
Linearity was tested with known concentrations of ENP, MET, GLB and GMP i.e. 
2.5, 5, 10, 25, 50 and 100 μgmL−1 respectively. Injected concentrations versus area 
were plotted and the correlation coefficients were calculated which are shown in 
Table 7.
Figure 1. 
















ENP 3.6 2.6 3200 1.23 3.3 2.48
MET 2.4 2.9 3250 1.25 3.5 2.56
GLB 8.5 2.89 3256 1.26 3.6 2.59
GMP 10.9 2.69 3246 1.28 3.9 2.69
Table 6. 
System suitability parameters.
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3.1.2.3 Accuracy
Method accuracy was evaluated as the percentage of recovery by estimation of 
all investigated analytes in presence of various commonly used tablets’ excepients at 
three levels of concentrations that were 80, 100 and 120%. Each sample was injected 
five times and accuracy was determined in range of 98.6–102.3% (Table 8). No sig-
nificant difference observed between amounts added and recovered without serum 
and with serum. Thus, used excepients did not interfere with active present in tablets.
3.1.2.4 Precision
Precision was evaluated by carrying out six independent sample preparation of 
a single lot of formulation. The sample solution was prepared in the same manner 
as described in sample preparation. Percentage relative standard deviation (%RSD) 
was found to be less than 2% for within a day and day to day variations, which 
proves that method is precise. Results are shown in Table 9.
3.1.2.5 Sensitivity
The limit of quantitation (LOQ ) of the method as signal/noise of ENP, MET, 
GLB and GMP were found to be 4.6, 0.96, 0.58 and 0.32 μgmL−1 respectively. 
Drugs Conc. μgmL−1 Regression Equation r2 LOD LOQ
μgmL−1
ENP 2.5–100 y = 2489.4x + 255.5 0.9996 1.53 4.6
MET 2.5–100 y = 10406x + 24139 0.9993 0.317 0.96
GLB 2.5–100 y = 14651x + 33832 0.9998 0.19 0.58
GMP 2.5–100 y = 15438x + 39969 0.9996 0.1 0.32
Table 7. 
Regresssion statistics LOD and LOQ.
Analytes Assay (spiking method) Assay in serum
Conc. μgmL-1 %RSD % Rec %RSD %Rec
ENP 8 0.011 101 0.9 100.3
10 0.326 100.3 0.23 101.23
12 0.001 100 0.8 102
MET 8 0.007 100.6 0.96 101
10 0.002 100.9 0.56 99.98
12 0.001 100.5 0.89 101.3
GLB 8 0.008 99.7 0.69 99.69
10 0.002 99.9 0.69 101.6
12 0.001 100 1.03 102.3
GMP 8 0.008 99.7 0.89 101.3
10 0.002 100.2 0.36 98.36
12 0.001 100.1 1.02 99.89
Table 8. 
Accuracy of ENP and NIDDM drugs.
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Similarly a signal/noise of 3, a LOD of ENP, MET, GLB and GMP were determined 
to be 1.53, 0.317, 0.19, and 0.1 μgmL−1 respectively.
3.1.2.6 Ruggedness
The ruggedness of this method was calculated in two different labs with two 
different instruments. The method did not show any notable deviations in results 
from acceptable limits.
3.1.2.7 Robustness of method
To evaluate the robustness of the developed RP-HPLC method, small deliberate 
variations in the optimized method parameters were done. The effect of change in 
flow rate, pH and mobile phase ratio on the retention time and tailing factor were 
studied. The method was found to be unaffected by small changes like ±0.1 change 
in pH, ± 0.1 change in flow rate and ± 1 change in mobile phase.
Drugs Conc. injected μgmL−1 Inter-day Intra-day
%RSD %Rec %RSD %Rec
ENP 2.5 0.4 97.44 0.96 100.9
5 0.3 100.5 0.63 101.1
10 0.2 99.87 0.65 99.49
25 0.11 99.2 0.63 101.2
50 0.56 100.8 0.62 98.94
100 0.36 99.92 0.62 101.1
MET 2.5 0.35 97.4 0.63 100.9
5 0.36 102 0.89 101.1
10 0.9 99.5 0.5 100.9
25 0.56 101 0.63 100.5
50 0.25 101 0.36 99.45
100 1 100 0.63 100.6
GLB 2.5 1.2 97.6 0.07 100
5 1.3 100.8 1.56 101
10 1.02 100 0.56 101
25 1.03 102 0.57 101
50 1.03 100.2 0.63 99.1
100 1.05 101.8 0.69 99.6
GMP 2.5 0.69 99.2 0.36 98.85
5 0.65 102 1.02 99.5
10 0.68 100 0.9 100.55
25 1.65 102 0.9 101.19
50 0.07 100.1 1.2 98.14
100 0.36 101.6 0.65 99.58
Table 9. 
Inter day and intraday precision of ENP and NIDDM drugs.
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3.2  Simultaneous determination of captopril and antidiabetic drugs 
(metformin, pioglitazone and glibenclamide)
The aim of the present study was to establish an efficient, reliable, accurate, 
precise and sensitive method for the separation and quantitative determination of 
both drugs simultaneously. These drugs belonged to different classes that could be 
co-administrated in a number of cases. Simultaneous determination of these drugs 
is desirable as this would allow more efficient generation of clinical data and could 
be performed at more modest cost than separate assays. We have developed the 
method for the simultaneous determination of captopril, metformin, pioglitazone 
and glibenclamide. The method has been validated according to ICH guidelines 
and was found to be reproducible. Further, this validated method was used to study 
the possible in vitro interactions of captopril with (metformin, pioglitazone and 
glibenclamide). Several problems were resolved in the simultaneous determination 
of compounds investigated.
3.2.1 Method optimization and chromatographic conditions
To optimize the operating conditions for isocratic RP-LC detection of all ana-
lytes, a number of parameters such as the mobile phase composition, pH and the 
flow rate were varied. Various ratios (50:50, 60:40, 70:30 v/v) of methanol: water 
were tested as starting solvent for system suitability study. The variation in the 
mobile phase leads to considerable changes in the chromatographic parameters, 
like peak symmetry, capacity factor and retention time. The pH effect showed that 
optimized conditions are reached when the pH value is 2.8, producing well resolved 
and sharp peaks for all drugs assayed. However, the ratio of (70:30 v/v) methanol: 
water pH adjusted to 2.8 with phosphoric acid as mobile phase (filtered through a 
0.45 micron filter), a flow rate of 1.0 mLmin−1 using wavelength 230 nm was chosen 
as optimal condition. Retention time for captopril was found to be 3.3 minute, met-
formin, pioglitazone and glibenclamide 2.4, 2.8, 7.2 minutes respectively (Figure 2).
3.2.2 Method validation
The developed method was validated by ICH guidelines [5]. It includes various 
parameters for example system suitability, selectivity, specificity, linearity, accuracy 
test, precision, robustness, ruggedness, sensitivity, limit of detection and quantifi-
cation (Table 10).
3.2.2.1 Linearity
Linearity was studied by preparing standard solutions at different concentra-
tion levels. The linearity range for CAP and antidiabetics was found to be 2.5–100 
μgmL−1 and 0.625–25 μgmL−1, respectively, regression equations for CAP and 
antidiabetics are given in Table 11.
3.2.2.2 Accuracy
Method accuracy was evaluated as the percentage of recovery by estimation of 
all investigated analytes in presence of various commonly used tablets’ excepients 
at three levels of concentrations that were 80, 100 and 120%. Each sample was 
injected five times and accuracy was determined in range of 98.45–102.2%. No 
significant difference was observed between amounts added and recovered without 
serum and with serum (Table 12).
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3.2.2.3 Precision
Precision was evaluated by carrying out six independent sample preparations of 
a single lot of formulation. The sample solution was prepared in the same manner 
as described in sample preparation. Percentage relative standard deviation (%RSD) 
was found to be less than 2% for within a day and day to day variations, which 
proves that method is precise (Table 13).
3.2.2.4 Sensitivity
The limit of quantitation (LOQ ) of the method as signal/noise of CAP, MET, 
PGL and GLB were found to be 2.3, 1.5, 2.3and 2.3 μgmL−1 respectively. Similarly a 
signal/noise of 3, a LOD of CAP, MET, PGL and GLB were determined to be 0.7, 0.4, 
0.7, and 0.7 μgmL−1, respectively.
Figure 2. 
A representative chromatogram of (a) metformin (b) pioglitazone (c) captopril and (d) glibenclamide in 
formulation.
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3.2.2.5 Ruggedness
Ruggedness of this method was evaluated in two different labs with two differ-

















CAP 3.3 2.13 3200 1.23 3.4 2.48
MET 2.4 2.25 3250 1.25 3.5 2.36
PGL 2.8 2.36 3250 1.36 3.6 2.59
GLB 7.2 2.36 3246 1.69 3.3 2.56
Table 10. 
System suitability parameters.
Drugs Conc. μgmL−1 Regression equation r2 LOD LOQ
μgmL−1
CAP 2.5–100 A = 2501.7x + 3073.7 0.9995 0.7 2.3
MET 2.5–100 A = 3841.3x + 4744.2 0.9998 0.4 1.5
PIO 2.5–100 A = 2419.8x + 2988.8 0.9995 0.7 2.3
GLB 2.5–100 A = 2419.8x + 2988.8 0.9995 0.7 2.3
Table 11. 
Regression characteristics.
Analyte Assay (spiking method) Assay in serum
Conc. μgmL−1 %RSD % Rec %RSD %Rec
CAP 8 0.01 99.98 0.002 102
10 0.33 100.04 0.02 101
12 0.36 99.97 0.03 101
MET 8 0.01 100 0.002 101
10 0 100.02 0.002 101.3
12 0.3 99.98 0.02 100.3
PGL 8 0.22 99.3 0.03 100.2
10 0.4 99.98 0.036 100.6
12 99.73 79.79 0.3 101.3
GLB 8 0.01 99.73 0.06 101.3
10 0.3 100.24 0.05 101.6
12 0.5 100.06 0.06 102.0
Table 12. 
Accuracy of captopril and antidiabetic drugs.
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3.2.2.6 Robustness of method
To evaluate the robustness of the developed RP-HPLC method, small deliberate 
variations in the optimized method parameters were done. The effect of change in 
flow rate, pH and mobile phase ratio on the retention time and tailing factor were 
studied. The method was found to be unaffected by small changes like ±0.1 change 
in pH, ± 0.1 change in flow rate and ± 1 change in mobile phase.
3.3  Simultaneous determinations of lisinopril, pioglitazone, glibenclamide  
and glimepiride
There is no method reported for the simultaneous determination of LSP and 
antidiabetic drugs using HPLC however there are methods for the determination 
of lisinopril [118, 119], similarly, there are methods reported for the simultaneous 
analysis of anti-diabetics. An isocratic reversed phase high-performance liquid 
Drugs Conc. injected μgmL−1 Inter-day Intra-day
%RSD %Rec %RSD %Rec
CAP 2.5 0.0073 101.11 0.073 101.11
5 0.0109 102.36 0.009 102.36
10 0.3261 100 0.361 100.02
25 0.0009 100 0.09 100.03
50 0.0005 99.826 0.005 99.26
100 0.0002 99.998 0.002 99.98
MET 1.25 0.0047 99.997 0.047 99.9
2.5 0.0071 99.988 0.071 99.88
5 0.0024 100.12 0.024 100.1
10 0.0006 99.983 0.006 99.93
25 0.0006 99.968 0.006 99.98
50 0.0003 99.991 0 99.91
PGL 1.25 0.0075 98.72 0.007 98.72
2.5 0.0075 99.98 0.075 99.98
5 0.0019 99.73 0.019 99.73
10 0.0012 99.97 0.012 99.87
25 0.0005 99.97 0.005 99.87
50 0.0003 100.02 0.003 100.1
GLB 1.25 0.008 100.02 0.08 100.2
2.5 0.008 99.783 0.008 99.7
5 0.002 99.983 0.002 99.9
10 0.001 99.972 0.001 99.9
25 5.00E-04 99.996 5.00E-04 99.9
50 3.00E-04 99.997 3.00E-04 99.9
Table 13. 
Inter day and intraday precision of captopril and NIDDM drugs.
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chromatographic (RP-HPLC) method has been developed for the simultaneous 
determination of lisinopril and antidiabetic drugs pioglitazone, glibenclamide and 
glimepride in bulk, dosage formulations and human serum and used for interaction 
studies.
3.3.1 Method optimization and chromatographic conditions
To develop a precise, accurate and suitable RP- HPLC method for the simultaneous 
estimation of LSP with antidiabetic drugs, different mobile phases were tried and the 
proposed chromatographic conditions were found to be appropriate for the quantita-
tive determination. The short analysis time (<8 min) also enables its application in 
routine and quality-control analysis of finished products. pH of mobile phase contain-
ing methanol: water (80:20),was adjusted to 2.9 with phosphoric acid.The mobile 
phase was filtered on a 0.45 micron filter and then sonicated for 10 min. The flow 
rate was set to 1.0 mLmin−1. The retention time for LSP was found to be 2.0 minute 
pioglitazone 2.6 minute, for glibenclamide was 5.3 minute and glimepride 6.1 minute.
3.3.2 Method validation
The developed method was validated by ICH guidelines, it includes system 
suitability, selectivity, specificity, linearity, accuracy test, precision, robustness, 
ruggedness, sensitivity, limit of detection and quantification.
3.3.2.1 System suitability
The HPLC system was equilibrated initially with the mobile phase, followed 
by 6 injections of the same standard to evaluate the system suitability on each day 
of method validation. Parameters of system suitability are peaks symmetry (sym-
metry factor), theoretical plates of The column, resolution, mass distribution ratio 
(capacity factor) and relative retention as summarized in Table 14.
3.3.2.2 Linearity
Linearity was studied by preparing standard solutions at different concentration 
levels. The linearity range for LSP, PGL, GLB and GMP was found to be 2.5–100 
μgmL−1. The regression equation for LSP and antidiabetic drugs were given in 
Table 15.
3.3.2.3 Accuracy
The accuracy of the method was evaluated as the percent recovery by estimation 
of all investigated analytes in presence of various commonly used tablets’ exce-
pients at three levels of concentrations that were 80, 100 and 120%. Each sample 
was injected five times and accuracy was determined in range of 98.45–102.2%. No 
significant difference observed between amounts added and recovered without 
serum and with serum (Table 16). Thus, used excepients did not interfere with 
active present in tablets (Figure 3).
3.3.2.4 Ruggedness
Ruggedness of the method was calculated in two different labs with two dif-
ferent instruments. The method did not show any notable deviations from accept-
able limits.
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3.3.2.5 Precision
Precision was evaluated by carrying out six independent sample preparation of 
a single lot of formulation. The sample solution was prepared in the same manner as 
described earlier. Relative standard deviation was found to be less than 2% for within 
















LSP 2 2.13 3200 1.23 3.4 2.3
PGL 2.6 2.25 3250 1.25 3.2 2
GLB 5.3 2.36 3250 1.23 3.6 2.59
GMP 6.1 2.5 3246 1.25 3.3 2.1
Table 14. 
System suitability parameters.
Drugs Conc. μgmL−1 Regression equations r2 LOD LOQ
μgmL−1
LSP 2.5–100 y = 1788.4x + 2214 0.9995 0.53 1.6
PGL 2.5–100 y = 2419.8x + 2988.8 0.9995 0.07 0.23
GLB 2.5–100 y = 17605x + 14118 0.9992 0.09 0.29
GMP 2.5–100 y = 15254x + 21932 0.9992 0.04 0.12
Table 15. 
Regression statistics LOD and LOQ.
Analyte Assay (spiking method) Assay in serum
Conc. μgmL−1 %RSD % Rec %RSD %Rec
LSP 8 0.23 100 36 102
10 0.326 100.23 54 100.36
12 0.23 99.9 0.96 100.69
PGL 8 0.28 100 1.2 99.98
10 0.36 100 1.3 101.3
12 0.001 100 1.02 101.3
GLB 8 0.96 99.7 1.03 100.2
10 0.96 99.9 1.05 102.02
12 0.26 101 1.06 101.3
GMP 8 0.56 99.7 1.02 101.3
10 0.32 100.2 0.69 100.69
12 0.69 100.2 0.96 102.03
Table 16. 
Accuracy of LSP and NIDDM drugs.
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3.3.2.6 Sensitivity
Limits of quantitation of the method as signal/noise of 10, for lisinopril, pio-
glitazone, glibenclamide and glimepride were found to be 1.6, 0.23, 0.29 and 0.12 
μgmL−1respectively. Similarly a signal/noise of 3, LOD of lisinopril, pioglitazone glib-
enclamide and glimepiride were determined to be 0.53, 0.07, 0.09 and 0.04 μgmL−1.
Figure 3. 
A representative chromatogram of (1) lisinopril (2) pioglitazone (3) glibenclamide and (4) glimepride in 
formulation and serum.
Drugs Conc. injected Inter-day Intra-day
μgmL−1 %RSD %Rec %RSD %Rec
LSP 2.5 0.3 100.9 1.3 100.8
5 0.36 101.1 1.3 101
10 0.6 99.49 1.6 100.4
25 0.9 101.2 0.6 101.2
50 0.6 99.32 1.5 100
100 0.26 100.2 1.08 100
PGL 2.5 1.3 100.9 1.03 99.9
5 1.3 101.1 1.02 100.2
10 1.2 100.9 1.32 100.2
25 0.3 100.5 1.02 101.2
50 0.65 99.45 0.3 98.9
100 0.36 100.6 0.96 101.2
GLB 2.5 1.3 100.0 1.02 100
5 1.2 101.0 0.63 100
10 1.0. 101.0 1.03 100
25 1.02 100.0 1.02 100
50 1.23 99.1 1.023 100
100 1.23 99.6 1.03 99.6
GMP 2.5 1.6 98.85 1.02 100.2
5 0.3 99.5 1.03 100.02
10 1.0 100.5 0.36 100.55
25 0.02 101.1 0.36 100.23
50 10.2 98.1 0.23 100.3
100 1.02 99.5 0.65 99.89
Table 17. 
Inter day and intraday precision of LSP and N1DDMdrugs.
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3.3.2.7 Robustness of method
To evaluate the robustness of the developed RP-HPLC method, small deliberate 
variations in the optimized method parameters were done. The effect of change in 
flow rate, pH and mobile phase ratio on the retention time and tailing factor were 
studied. The method was found to be unaffected by small changes like ±0.1 change 
in pH, ± 0.1 change in flow rate and ± 1 change in mobile phase.
3.4 Interaction of ACE inhibitors with antidiabetic drugs
Hypertension in diabetics represents an important health problem as the combi-
nation of these diseases is common, carries significant morbidity and mortality and 
is frequently difficult to treat. The prevalence of hypertension in diabetic people 
is probably 1.5–2 times higher than in the general population [118]. Reduction of 
cardiovascular risk is therefore a high priority in the management of diabetes. 
Micro albuminuria is an important predictor of cardiovascular events and forms 
one of the components of insulin resistance/metabolic syndrome, which confers a 
particularly high risk of cardiovascular death [119]. Diverse classes of antihyperten-
sive prescription may be used for blood pressure manage in diabetes among these 
angiotensin-II type 1 receptor blockers (ARBs), calcium channel blockers, thiazide 
diuretics and ACE inhibitors are common [120]. Cheung demonstrated that the cal-
cium antagonists have been extensively used in hypertensive patients with diabetes 
[121]. Use of Verapamil a calcium channel blocker significantly reduced the risk of 
developing diabetes [122]. Similarly diabetic patients often take anti-hypertensive 
medications and coadministered with antidiabetic drugs [123]. Treatment of 
patients with hypertension and diabetes with ARBs improved both macrovascular 
and microvascular alterations [124].
Diverse classes of antihypertensive prescription may be used for blood pres-
sure manage in diabetes among these calcium channel blockers, angiotensin-II 
type 1 receptor blockers (ARBs), thiazide diuretics and ACE inhibitors are com-
mon. Cheung demonstrated that calcium antagonists have been extensively used 
in hypertensive patients with diabetes. Collective pharmacological treatment 
generally entails in management of type 2 diabetes mellitus to attain satisfactory 
glucose manage and dealing of concomitant pathologies, drug–drug interactions 
must be cautiously considered with antihyperglycaemic drugs [125]. Mitra [126] 
conducted a study to examine the interaction of diabecon (D-400), a herbomineral 
anti-diabetic the most important purpose of this cram was to assess the “in vitro” 
drug interaction of enalapril, captopril and lisinopril with commonly prescribed 
antidiabetic drugs (metformin, pioglitazone glimepride and glibenclamide) by 
utilizing HPLC.
3.4.1 Interaction of enalapril with antidiabetic drugs by HPLC
In vitro interactions of enalapril in the presence of antidiabetic drugs (metfor-
min, glibenclamide and glimepride) were carried out in 1:1 at 37°C and method 
for simultaneous determination of both interacting drugs was also developed 
as described in former sections. Results of these interactions are summarized in 
Table 18 and plotted in Figure 4. The % availability of enalapril and metformin 
was found to be between 98 and 106% indicating no reaction between drugs. 
These results clearly indicated that enalapril could be safely co administered with 
metformin. The two drugs did not inhibit or disturb the absorption of each other. 
Similar behavior was observed with glibenclamide and glimepride, the availabil-
ity of enalapril was found to be between 102 and 103% with glibenclamide and 
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glimepride and the availability of glibenclamide and glimepride remained almost 
unchanged. No remarkable change in area under curve and drift in retention time 
were observed. However, the results showed that no interaction occurred as there % 
recovery remained almost unchanged.
3.4.2 Interaction of captopril with antidiabetic drugs by HPLC
In this study drugs were analyzed by measuring the area under curve (AUC), 
% recovery and considerable drift in retention time. Captopril and metformin did 
not affect the availabilities of each other i.e. 101% and 103% was observed respec-
tively up to 30 minutes and at the end of experiment both were available up to 
100% and 105% respectively. Similar effect was observed in presence of piogli-
tazone i.e. 102% of captopril, while 104% of pioglitazone was available at the end. 
In presence of glibenclamide, the %availability of captopril and glibenclamide 
were 102 and 101% at 30 minutes, which gradually increased and after 180 min 
were found to be103 and 106% respectively. Interacting results shows that no 
remarkable drifts in the availabilities and no drift in retention time were observed 
(Table 19). However the results showed that no interaction occurred as there was 
no significant change in % availabilities of both drugs were observed by HPLC.
Time ENP MET ENP GLB ENP GMP
0 99.89 100.01 100.34 100.34 102 99.99
30 99.65 99.02 99.54 99.54 101.3 100
60 100.23 95.31 98.12 98.99 102.3 101
90 101.61 105.56 99.69 99.69 102.3 102.3
120 100.2 98.3 98.46 98.46 101.2 102
150 101.98 98.88 100.3 100.63 102.3 103
180 106.46 99.99 100.36 100.36 102.3 104.3
Table 18. 
% availability of enalapril and antidiabetic drugs by HPLC.
Figure 4. 
% Availability of a inhibitors and antidiabetic drugs by HPLC.
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3.4.3 Interaction of lisinopril with antidiabetic drugs by HPLC
In this study drugs were analyzed by measuring the area under curve (AUC), % 
recovery and considerable drift in retention time. Presence of metformin, piogli-
tazone and glibenclamide could also not assert any significant change in availability 
of lisinopril at 37°C. Availability of lisinopril with metformin was 103.33 at the end 
of experiment and that of metformin was 104.33%. In presence of pioglitazone and 
glibenclamide 100.3 and 102% of drug was available at the end of experiment and 
the availability of pioglitazone and glibenclamide were also not affected in presence 
of lisinopril. The obtained results showed that the NIDDMs and lisinopril do not 
affect in-vitro availability of each other at 37°C (Table 20).
4. Conclusions
The method described is simple, universal, convenient and reproducible simul-
taneous method that can be used to determine and quantify ACE inhibitors and 
antidiabetic drugs. Reliability, rapidness, simplicity, sensitivity, economical nature, 
good recovery and precision of this method give it an advantage over the other 
reported HPLC methods for the determination of ACE inhibitors and antidiabetic 
drugs. In summary, the proposed method can be used for drug analysis in routine 
quality control. In addition, this method has wide application in clinical research 
and pharmacokinetics drug interactions.
(mins) CAP MET CAP PGL CAP GLB
0 99.89 100.01 100.34 100.34 99.9 99
30 101 103 99.54 99.54 101.3 101
60 100.23 103.3 99.98 99.6 102.3 102.3
90 99.98 103.2 99.3 99.69 102.3 102.6
120 100.2 104 98.46 99.96 102 102
150 101.98 104.3 100.3 100.3 103.02 104.02
180 100.03 105.3 102 104 103 106.03
Table 19. 
% availability of captopril and antidiabetic drugs by HPLC.
mins LSP MET LSP PGL LSP GLB
0 99.89 100.01 100.34 100.34 100 99.2
30 99.65 100.3 99.54 100.3 101.7 101.3
60 100.23 100.8 99.98 100.6 100.5 101.3
90 99.98 101.3 99.3 100.9 101.3 101.02
120 101.3 102.5 100.3 101.3 101.3 101
150 101.98 103.6 100.3 102.3 102.01 102.5
180 103.33 104.0 101.36 102.3 103 103.2
Table 20. 
% Availability of lisinopril and antidiabetic drugs by HPLC.
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